Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 26,103 shares at $67.57 ($1.8M) on 2026-05-21, disclosed to the SEC on 2026-05-26.
Scheduled sale ($1.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.57 | 2,256 | $152K | 8.4% |
| 2 | $68.30 | 6,725 | $459K | 25.3% |
| 3 | $69.22 | 5,072 | $351K | 19.4% |
| 4 | $70.48 | 11,250 | $793K | 43.7% |
| 5 | $70.92 | 800 | $57K | 3.1% |
| Total | $69.44 avg | 26,103 |
| $1.8M |
| 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |
| BBIO | SELL | 2026-04-13 | $6.0M | — | Filing → |